Stockholders approve merger with Palvella; authorized shares increased 53x to 200M

PALVELLA THERAPEUTICS, INC.

Merger expected to close Dec. 13; pre-merger stockholders receive Contingent Value Rights.
Authorized shares increased from 3.75M to 200M; Series F Preferred redeemed for $0.01.
Proposal to issue shares in merger approved: 718,345 for, 4,199 against, 294,890 broker non-votes.
Name change to Palvella Therapeutics, Inc. and 2024 Equity Incentive Plan approved.
All proposals approved by requisite votes; no adjournment needed.

item 3.03 item 5.07 item 5.02 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

PALVELLA THERAPEUTICS, INC.: Increased authorized shares of common stock from 3,750,000 to 200,000,000 (effective 2024-12-12).

Change: charter amendment
Effective: 2024-12-12

Exact text from the filing

At the Special Meeting, the Company’s stockholders approved an amendment to the amended and restated articles of incorporation of the Company (the “Authorized Share Increase Amendment”) to implement an increase in the number of authorized shares of common stock from 3,750,000 to 200,000,000 (the “Share Increase”). On December 12, 2024, the Company filed the Share Increase Amendment with the Nevada Secretary of State to effect the Share Increase effective on December 12, 2024.

View on SEC.gov

101 governance changes filed in the last 30 days. Browse all governance changes →

PALVELLA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-037350

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.